Technology area: Biotechnology & Pharmaceuticals
11 pending office actions • 8 art units • 8 examiners • 0 of 11 (0%) have an AI response strategy ready
Orcosa Inc. is currently managing 12 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed among 9 distinct examiners, indicating a concentration of work where some examiners are handling multiple matters. The portfolio also spans 9 distinct art units, which suggests that the company's biotechnology filings are being reviewed across several different specialized groups within the patent office. This variety in art units requires a prosecution approach that accounts for different examination benchmarks and administrative cultures.
The busiest examiner for this portfolio is GONZALEZ, LUISALBERTO, who is responsible for 3 pending office actions. This means that a quarter of the 12 pending office actions are under the review of a single individual, making the relationship with GONZALEZ, LUISALBERTO a significant factor in the portfolio's overall progress. The remaining actions are spread across the other 9 distinct examiners and 9 distinct art units, providing some level of diversification. Practitioners should focus on the specific tendencies of the busiest examiner while also remaining prepared for the unique requirements of the 9 different art units involved in these 12 pending office actions.
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 3 (27%) |
| §112 only | 1 (9%) |
| Double-patenting only | 1 (9%) |
| Double-patenting + other | 2 (18%) |
| Multi-statute (no §101) | 4 (36%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GONZALEZ, LUISALBERTO | 3 | 59.7% | +46.3% |
| DAHLIN, HEATHER RAQUEL | 2 | 42.2% | +47.1% |
| REYNOLDS, STEVEN ALAN | 1 | 65.9% | +23.3% |
| BELL, SARA ELIZABETH | 1 | 68.8% | +38.2% |
| KETCHAM, KAREN A | 1 | 19.6% | +37.2% |
| ROBINSON, MIKHAIL O'DONNEL | 1 | 58.3% | +43.1% |
| HOERNER, PAUL ELLSWORTH | 1 | 50.6% | +62.3% |
| WORSHAM, JESSICA N | 1 | 56.6% | +56.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 5 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252741 | IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | BELL, SARA ELIZABETH | 89d overdue |
| 18252668 | CANNABINOIDS IN THE TREATMENT OF AUTISM SPECTRUM DISORDER | DAHLIN, HEATHER RAQUEL | 10d overdue |
| 18252707 | RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE | KETCHAM, KAREN A | — |
| 18252676 | RAPIDLY INFUSING COMPOSITIONS FOR ORAL MUCOSAL DELIVERY AND METHODS | GONZALEZ, LUISALBERTO | — |
| 18297364 | STICK COMPOSITION CONTAINING CANNABINOIDS | WORSHAM, JESSICA N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18252741 | IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | BELL, SARA ELIZABETH | 89d overdue |
| 18252688 | RAPIDLY DISINTERGRATING COMPOSITIONS AND METHODS (Nicotine) | GONZALEZ, LUISALBERTO | 60d overdue |
| 18252694 | IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF ALZHEIMER'S DISEASE | ROBINSON, MIKHAIL O'DONNEL | 23d overdue |
| 18252668 | CANNABINOIDS IN THE TREATMENT OF AUTISM SPECTRUM DISORDER | DAHLIN, HEATHER RAQUEL | 10d overdue |
| 19272094 | PACKAGING FOR RAPIDLY INFUSING COMPOSITION | REYNOLDS, STEVEN ALAN | — |
| 18252707 | RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE | KETCHAM, KAREN A | — |
| 18252676 | RAPIDLY INFUSING COMPOSITIONS FOR ORAL MUCOSAL DELIVERY AND METHODS | GONZALEZ, LUISALBERTO | — |
| 18252693 | METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY CONDITIONS WITH CANNABIDIOL OR ITS DERIVATIVES/ANALOGS | DAHLIN, HEATHER RAQUEL | — |
| Art Unit | Apps |
|---|---|
| 1624 | 3 |
| 1629 | 2 |
| 3735 | 1 |
| 1625 | 1 |
| 1614 | 1 |
| 1627 | 1 |
| 1611 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19272094 | PACKAGING FOR RAPIDLY INFUSING COMPOSITION | REYNOLDS, STEVEN ALAN | 3735 | DP | Non-Final OA | — | Pending | Jul 17, 2025 |
| 18252741 | IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF EPILEPSY | BELL, SARA ELIZABETH | 1625 | §103§112 | Final Rejection | 89d overdue | Pending | May 12, 2023 |
| 18252707 | RAPIDLY INFUSING CANNABINOID COMPOSITIONS, PROCESSES OF MANUFACTURE, AND METHODS OF USE | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | — | Pending | May 11, 2023 |
| 18252688 | RAPIDLY DISINTERGRATING COMPOSITIONS AND METHODS (Nicotine) | GONZALEZ, LUISALBERTO | 1624 | §103DP | Final Rejection | 60d overdue | Pending | May 11, 2023 |
| 18252676 | RAPIDLY INFUSING COMPOSITIONS FOR ORAL MUCOSAL DELIVERY AND METHODS | GONZALEZ, LUISALBERTO | 1624 | §103§112Other | Final Rejection | — | Pending | May 11, 2023 |
| 18252668 | CANNABINOIDS IN THE TREATMENT OF AUTISM SPECTRUM DISORDER | DAHLIN, HEATHER RAQUEL | 1629 | §103§112Other | Non-Final OA | 10d overdue | Pending | May 11, 2023 |
| 18252693 | METHODS OF TREATING AUTOIMMUNE OR INFLAMMATORY CONDITIONS WITH CANNABIDIOL OR ITS DERIVATIVES/ANALOGS | DAHLIN, HEATHER RAQUEL | 1629 | §103Other | Final Rejection | — | Pending | May 11, 2023 |
| 18252681 | RAPIDLY INFUSING COMPOSITIONS WITH SUPPLEMENTS AND TREATMENT METHODS | GONZALEZ, LUISALBERTO | 1624 | §103DP | Final Rejection | — | Pending | May 11, 2023 |
| 18252694 | IMPROVED USE OF CANNABINOIDS IN THE TREATMENT OF ALZHEIMER'S DISEASE | ROBINSON, MIKHAIL O'DONNEL | 1627 | §112 | Non-Final OA | 23d overdue | Pending | May 11, 2023 |
| 18307228 | RAPIDLY INFUSING PLATFORM AND COMPOSITIONS FOR THERAPEUTIC TREATMENT IN HUMANS | HOERNER, PAUL ELLSWORTH | 1611 | §103Other | Final Rejection | — | Pending | Apr 26, 2023 |
| 18297364 | STICK COMPOSITION CONTAINING CANNABINOIDS | WORSHAM, JESSICA N | 1615 | §103§112 | Non-Final OA | — | Pending | Apr 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialOrcosa Inc. has 11 pending office actions as of October 2026, spread across 8 art units and 8 examiners.
Luisalberto Gonzalez has the most, with 3 of Orcosa Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
